Search clinical trials for: universal CAR-T(UCAR-T)

Total 11955 results

920th Hospital of Joint Logistics Support Force...

Recruiting

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01) (CAR_21_01)

CAR-T Therapy Complications

Italy
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
Second Affiliated Hospital of Soochow University
Soochow T-Maximun Biotechnology Co. LTD

Recruiting

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

Advanced Glioma | Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy

China
The Lymphoma Academic Research Organisation
Novartis; Gilead Sciences

Recruiting

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment

France
Norwegian University of Science and Technology
Helse Nord-Trøndelag HF

Completed

Psychoeducational Groups for Adults With ADHD

Attention Deficit Hyperactivity Disorder

Norway
Henan Cancer Hospital
Fundamenta Therapeutics, Ltd.

Not yet recruiting

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Stiftung Swiss Tumor Institute
Klinik Hirslanden, Zurich; Palleos Healthcare GmbH

Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy (CARTePRO)

Patient Reported Outcome Measures | CAR T-Cell Therapy

Switzerland
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

CAR-T Cell Immunotherapy | Glioma of Brain
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
University of California, San Francisco

Withdrawn

Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy

Lymphoma | Leukemia | Plasma Cell Dyscrasia
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors

Melanoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Completed

Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes

Type2 Diabetes

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B Cell

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Nexcella Inc.

Not yet recruiting

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NEXICART-2)

Light Chain (AL) Amyloidosis

United States
Ruijin Hospital

Recruiting

Axi-cel Retreatment in Relapsed/Refractory LBCL

CAR-T Retreatment

China
Novartis Pharmaceuticals
University of Pennsylvania

Recruiting

CAR-T Long Term Follow Up (LTFU) Study (PAVO)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

United States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Relapse | CD19 Positive | Refractory

China
Yan'an Affiliated Hospital of Kunming Medical University
KAEDI

Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Platelet Transfusion Refractoriness | Acute Leukemia in Remission

China
Zhejiang University

Recruiting

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Hematological Malignancy

China
Guangzhou 8th People's Hospital
Sun Yat-sen University

Recruiting

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

HIV/AIDS

China
Guangzhou Bio-gene Technology Co., Ltd

Active, not recruiting

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

T-Cell Acute Lymphocytic Leukemia

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Zhao Weili

Not yet recruiting

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Zhejiang University
OriCell Therapeutics Co., Ltd.

Active, not recruiting

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
Minerva Biotechnologies Corporation
City of Hope Medical Center

Recruiting

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Metastatic Breast Cancer

United States
Xuanwu Hospital, Beijing
Baoding Children's Hospital

Recruiting

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
First Affiliated Hospital of Zhejiang University

Unknown

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Unknown

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia

China

Search clinical trials for: universal CAR-T(UCAR-T)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations